What type of study is this?

This is a Quantitative Study study.

Modern landscape of prior authorization burden at a specialty cancer pharmacy.

View Full Paper

Ask AI

Bookmark

Authors

This analysis reveals that 1 in 6 prior authorizations for anticancer drugs are denied, highlighting inefficiencies in patient care.

Overall, 16% of prior authorizations were denied, impacting patient access to necessary medications.
The median time to resolution for all prior authorizations was 1.3 days, indicating potential inefficiencies in the process.
Out of 5944 prior authorizations initiated, 5249 were for anticancer drugs, showing the focus on cancer treatment.
Denial rates were particularly high for supportive medications at 22%, suggesting a need for improved processes in this area.

Syed et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark